About the Authors
- Alexandra U. Scherrer
-
* E-mail: alexandra.scherrer@usz.ch
Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- Bruno Ledergerber
-
Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- Viktor von Wyl
-
Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- Jürg Böni
-
Affiliation Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zürich, Zürich, Switzerland
- Sabine Yerly
-
Affiliation Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
- Thomas Klimkait
-
Affiliation Institute for Medical Microbiology, University of Basel, Basel, Switzerland
- Cristina Cellerai
-
Affiliation Division of Immunology and Allergy, University Hospital Lausanne, Lausanne, Switzerland
- Hansjakob Furrer
-
Affiliation Division of Infectious Diseases, University Hospital Berne, University of Berne, Berne, Switzerland
- Alexandra Calmy
-
Affiliation Division of Infectious Diseases, University Hospitals Geneva, Geneva, Switzerland
- Matthias Cavassini
-
Affiliation Infectious Diseases Service, University Hospital Lausanne, Lausanne, Switzerland
- Luigia Elzi
-
Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland
- Pietro L. Vernazza
-
Affiliation Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
- Enos Bernasconi
-
Affiliation Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland
- Huldrych F. Günthard
-
Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland
- and the Swiss HIV Cohort Study (SHCS)
-
¶Membership of the Swiss HIV Cohort Study is provided in the Acknowledgments.
Competing Interests
The authors have the following interests: HFG has been an adviser and/or consultant for the following companies: GlaxoSmithKline, Abbott, Novartis, Boehringer Ingelheim, Roche, Tibotec and Bristol-Myers Squibb, and has received unrestricted research and educational grants from Roche, Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Tibotec and Merck Sharp and Dohme (all money went to institution). SY has participated in advisory boards of Bristol-Myers Squibb and Tibotec, and has received travel grants from GlaxoSmithKline and Merck Sharp and Dohme. TK served as advisor for Bristol-Myers Squibb and Pfizer and has received travel grants from Abbott and Pfizer. This study was funded by a research grant from the Union Bank of Switzerland in the name of a donor to HFG, an unrestricted research grant from Tibotec, Switzerland to HFG and from Gilead, Switzerland to HFG. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Performed the experiments: JB SY CC TK. Analyzed the data: AUS VvW BL. Contributed reagents/materials/analysis tools: HFG AC MC LE PLV EB HF. Wrote the paper: AUS HFG.